Cargando…

Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs

BACKGROUND: Payers in the United States issue coverage determinations to guide how their enrolled beneficiaries use prescription drugs. Because payers create their own coverage policies, how they cover drugs can vary, which in turn can affect access to care by beneficiaries. OBJECTIVE: To examine ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chambers, James D., Wilkinson, Colby L., Anderson, Jordan E., Chenoweth, Matthew D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2016
Materias:	Research Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397684/ https://www.ncbi.nlm.nih.gov/pubmed/27668566 http://dx.doi.org/10.18553/jmcp.2016.22.10.1176

Ejemplares similares

Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies
por: Chambers, James D., et al.
Publicado: (2018)

Private Payer Coverage Policies for ApoE-e4 Genetic Testing
por: Arias, Jalayne J., et al.
Publicado: (2021)

A Private Payer Persective
por: Shurney, Dexter W.
Publicado: (2006)

Analysis of Drug and Administrative Costs Allowed by U.S. Private and Public Third-Party Payers for 3 Intravenous Biologic Agents for Rheumatoid Arthritis
por: Stavrakas, Spyros, et al.
Publicado: (2011)

US public and private payer coverage for tobacco cessation treatments and barriers to accessing treatments
por: Hussain, Radha, et al.
Publicado: (2022)

An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective
por: Claxton, Lindsay, et al.
Publicado: (2018)

Variability in Private Payer Medical Policies for Osteochondral Allograft Transplantation Demonstrates the Absence of Standardization in Medical Criteria Between Payers
por: Tabbaa, Suzanne M., et al.
Publicado: (2022)

Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market
por: Shih, Ya-Chen Tina, et al.
Publicado: (2021)

How do Medicare Physician Fees Compare With Private Payers?
por: Miller, Mark E., et al.
Publicado: (1993)

Private Payer Coverage Policies for Whole Exome Sequencing (WES) in Pediatric Patients: Trends Over Time and Analysis of Evidence Cited
por: Douglas, Michael P., et al.
Publicado: (2018)

Actuarial Analysis of Private Payer Administrative Claims Data for Women With Endometriosis
por: Mirkin, David, et al.
Publicado: (2007)

Specialty Pharmacy Cost Management Strategies of Private Health Care Payers
por: Stern, Debbi, et al.
Publicado: (2006)

Variation in health plan specialty drug coverage: an empirical analysis
por: Margaretos, Nikoletta M., et al.
Publicado: (2019)

Payer perceptions and use of value assessment tools in the United States
por: Westrich, Kimberly, et al.
Publicado: (2023)

Geographic variation in cesarean delivery in the United States by payer
por: Henke, Rachel Mosher, et al.
Publicado: (2014)

Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience
por: Watkins, John B., et al.
Publicado: (2006)

Disparity in clinical outcomes after cardiac surgery between private and public (NHS) payers in England
por: Benedetto, Umberto, et al.
Publicado: (2020)

Are payers treating orphan drugs differently?
por: Cohen, Joshua P., et al.
Publicado: (2014)

Comment on: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
por: Liedgens, Hiltrud, et al.
Publicado: (2013)

Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US
por: Walton, Alison, et al.
Publicado: (2021)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Patient Perception of Cardiovascular Risk in Rheumatoid Arthritis
por: Banerjee, Shubhasree, et al.
Publicado: (2020)

Barriers From Third-Party Payers to Biologic Use in Pediatric Inflammatory Bowel Disease
por: Lepus, Chelsea A., et al.
Publicado: (2022)

All-payer ratesetting: Down but not out
por: Anderson, Gerard F.
Publicado: (1992)

Trends in Shoulder Stabilization Techniques Used in the United States Based on a Large Private-Payer Database
por: Riff, Andrew J., et al.
Publicado: (2017)

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
por: Epstein, Robert S
Publicado: (2021)

Association of Emergency Department Payer Mix with ED Receipt of Telehealth Services: An Observational Analysis
por: Zachrison, Kori S., et al.
Publicado: (2022)

Biologics Initiation in Rheumatoid Arthritis by Race and Ethnicity: Results From a Randomized Survey Study
por: Simard, Julia F., et al.
Publicado: (2023)

Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function
por: Liphardt, Anna‐Maria, et al.
Publicado: (2020)

Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives
por: Arrieta, Alejandro, et al.
Publicado: (2017)

The Social Contexts of Birthing People with Public- and Private-Payer Prenatal Care: Illuminating an Understudied Aspect of the Patient Experience
por: Garrett, Sarah B., et al.
Publicado: (2022)

Hospitals and the Tax-Payer
Publicado: (1920)

Variation in Medicaid and commercial coverage of cell and gene therapies
por: Beinfeld, Molly T., et al.
Publicado: (2023)

A cost–benefit analysis of smoking cessation prescription coverage from a US payer perspective
por: Baker, Christine L, et al.
Publicado: (2018)

The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis
por: Heidari, Behzad, et al.
Publicado: (2009)

Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population
por: Wang, Ching-Yu, et al.
Publicado: (2022)

Antioxidant intervention in rheumatoid arthritis: results of an open pilot study
por: van Vugt, Richard M., et al.
Publicado: (2008)

Subclinical atherosclerosis in rheumatoid arthritis patients of the Gulf Cooperated Council
por: Hannawi, Suad MA., et al.
Publicado: (2020)

Metabolic Effects of Anti-TNF-α Treatment in Rheumatoid Arthritis
por: Macáková, Kristína, et al.
Publicado: (2023)

The private sector and universal health coverage
por: Clarke, David, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_teuva8bqtof4kdcoknbcb2gprp